1. Geddawy, A., M. Hussian, M.Y. Kamel, R. Kamal and M.A. Ibrahim, 2017. Effects of liraglutide and vitamin E in fructose-induced metabolic syndrome in rats. Pharmacology, 99: 48-56.
   CrossRef  |  Direct Link  |  
2. Abdel-Aziz, A.M., M.A. Ibrahim, A.A. El-Sheikh, M.Y. Kamel, N.M. Zenhom, S. Abdel-Raheim and H. Abdelhaleem, 2017. Effect of sofosbuvir plus daclatasvir in hepatitis C virus genotype-4 patients: Promising effect on liver fibrosis. J. Clin. Exp. Hepatol. 10.1016/j.jceh.2017.06.006.
   CrossRef  |  Direct Link  |  
3. Morsy, M.A., M.A. Ibrahim and M.I. Abd-Elghany, 2016. Dimethyl dimethoxy biphenyl dicarboxylate attenuates hepatic and metabolic alterations in high fructose-fed rats. Toxicol. Ind. Health, 32: 59-67.
   CrossRef  |  Direct Link  |  
4. Hafez, H.M., M.A. Ibrahim, S.A. Ibrahim, E.F. Amin, W. Goma and A.M. Abdelrahman, 2015. Potential protective effect of etanercept and aminoguanidine in methotrexate-induced hepatotoxicity and nephrotoxicity in rats. Eur. J. Pharmacol., 768: 1-12.
   CrossRef  |  Direct Link  |  
5. Abdel-Gaber, S.A., M.A. Ibrahim, E.F. Amin, S.A. Ibrahim, R.K. Mohammed and A.M. Abdelrahman, 2015. Effect of selective versus non-selective cyclooxygenase inhibitors on ischemia-reperfusion-induced hepatic injury in rats. Life Sci., 134: 42-48.
   CrossRef  |  Direct Link  |  
6. Ibrahim, M.A., S.A. Abdel-Gaber, E.F. Amin, S.A. Ibrahim, R.K. Mohammed and A.M. Abdelrahman, 2014. Molecular mechanisms contributing to the protective effect of levosimendan in liver ischemia-reperfusion injury. Eur. J. Pharmacol., 741: 64-73.
   CrossRef  |  Direct Link  |  
7. Ibrahim, M.A., A.A. El-Sheikh, H.M. Khalaf and A.M. Abdelrahman, 2014. Protective effect of peroxisome proliferator activator receptor (PPAR)-α and-γ ligands against methotrexate-induced nephrotoxicity. Immunopharmacol. Immunotoxicol., 36: 130-137.
   CrossRef  |  Direct Link  |  
8. Gomaa, W.M., M.A. Ibrahim and M.E. Shatat, 2014. Overexpression of cyclooxygenase-2 and transforming growth factor-beta 1 is an independent predictor of poor virological response to interferon therapy in chronic HCV genotype 4 patients. Saudi J. Gastroenterol., 20: 59-65.
   CrossRef  |  Direct Link  |  
9. Amin, E.F., M.A. Ibrahim, S.A. Ibrahim, R.R. Rofaeel and A.M. Abdelrahman, 2014. Mechanisms underlying the protective effect of sildenafil in metabolic syndrome in rats. Minia J. Med. Res., 25: 31-44.
10. Ibrahim, M.A., M. Kelleni and A. Geddawy, 2013. Nonalcoholic fatty liver disease: Current and potential therapies. Life Sci., 92: 114-118.
    CrossRef  |  Direct Link  |  
11. Ibrahim, M.A., M.A. Morsy, O.M. Ashour and M.I. Abdel-Ghany, 2012. Protective effects of chloroquine on high fructose-induced metabolic alterations and hepatic injury in rats. J. Egypt. Soc. T., 45: 55-62.
12. Ibrahim, M.A., M.A. Morsy, H.M. Hafez, W.M. Gomaa and A.M. Abdelrahman, 2012. Effect of selective and non-selective cyclooxygenase inhibitors on doxorubicin-induced cardiotoxicity and nephrotoxicity in rats. Toxicol. Mech. Methods, 22: 424-431.
    CrossRef  |  Direct Link  |  
13. Ibrahim, M.A., 2012. Rational use of drugs: A possible role of open access journals. Biochem. Pharmacol., Vol. 1. 10.4172/2167-0501.1000e125.
    CrossRef  |  Direct Link  |  
14. Ibrahim, M.A., A.H. Saad and H.M. Abdelghani, 2011. Nitric oxide in acute liver injury: The controversy will continue. J. Egypt. Soc. T., 44: 77-84.
15. Ibrahim, M.A., A. Saad, S. Abdelwahab and H. Abdelghany, 2011. Molecular mechanisms underlying the protective effect of telmisartan in non-alcoholic fatty liver disease: Role of proinflammatory enzymes. Egypt. J. Basic Clin. Pharmacol., 1: 1-8.
16. Ibrahim, M., E. Farghaly, W. Gomaa, M. Kelleni and A.M. Abdelrahman, 2011. Nitro-aspirin is a potential therapy for non alcoholic fatty liver disease. Eur. J. Pharmacol., 659: 289-295.
    CrossRef  |  Direct Link  |  
17. Ibrahim, M.A., W. Gomaa, Y. Ibrahim, H. El Hadad and M. Shatat et al., 2010. Nitric oxide levels and sustained virological response to pegylated-interferon alpha2a plus ribavirin in chronic HCV genotype 4 hepatitis: A prospective study. J. Gastrointestin. Liver Dis., 19: 387-392.
18. Ibrahim, M.A., E. Farghaly, W. Gomaa, M. Kelleni and A. Abdelrahman, 2010. Ezetimibe inhibits proinflammatory mediators involved in the pathogenesis of non alcoholic fatty liver disease. Egypt. J. Med. Sci., 31: 247-269.
19. Ibrahim, M.A., O.M. Ashour, Y.F. Ibrahim, H.I. El-Bitar, W. Gomaa and S.R. Abdel-Rahim, 2009. Angiotensin-converting enzyme inhibition and angiotensin AT₁-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharmacol. Res., 60: 373-381.
    CrossRef  |  Direct Link  |  
20. Ibrahim, M.A., T. Kanzaki, A.H. Saad and A.M. Mahmoud, 2008. Nitric oxide and fibronectin in cardiac tissue of diabetic hypertensive rats: Effect of captopril. El-Minia Med. Bull., 19: 328-339.
21. Ibrahim, M.A., T. Kanzaki, S.I. Yamagata, N. Satoh and S. Ueda, 2005. Effect of diabetes on aortic nitric oxide synthesis in spontaneously hypertensive rats: Does captopril modulate this effect? Life Sci., 77: 1003-1014.
    CrossRef  |  Direct Link  |  
22. Ibrahim, M.A., H. Asai, S. Satoh, N. Satoh and S. Ueda, 2004. Effect of zaprinast on nitric oxide levels in serum and aortic tissue. Methods Find. Exp. Clin. Pharmacol., 26: 19-24.
    CrossRef  |  Direct Link  |  
23. Ibrahim, M.A., N. Satoh and S. Ueda, 2003. Possible impact of nitric oxide on the antihypertensive effect of captopril and zaprinast. Adv. Ther., 20: 143-148.
    CrossRef  |  Direct Link  |